EpiThany Inc. logo

EpiThany Inc.

EpiThany is a clinical-stage biotech company developing cancer vaccines targeting tumor-associated antigens that stimulate selective and self-escalating T cell immunity.

EpiThany was launched in 2014 capitalizing on the R&D platform developed at the Tumor Vaccine Group at the University of Washington by pioneering cancer vaccine researcher Nora Disis, scientific co-founder of the company.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://epithany.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
3240 Fuhrman Ave E #106, WA 98102,
Seattle,
United States
Email
Contact Number
+1 2069923047

In May 2017, EpiThany signed a clinical collaboration with Merck KGaA and Pfizer to evaluate avelumab, a human anti-PD-L1 antibody, and EP-101 STEMVAC, in a Ph II trial in women with breast cancer. Under the terms of the agreement, EpiThany will be responsible for conducting the Phase 2 clinical trial in breast cancer.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]

EpiThany technology enables the targeting of myriad tumor antigens across a spectrum of cancers, yielding a deep pipeline of Th1-selective anti-cancer vaccines.

EP-101 STEMVAC is a T-helper Type 1 (Th1)-selective, multi-antigen DNA vaccine designed to induce a robust and targeted anti-tumor immune response. Preclinical results have demonstrated the ability of EP-101 to induce a cytotoxic immune response to vaccine antigens and have demonstrated efficacy and stem cell targeting in breast cancer models.